Edaravone
What is Edaravone?[edit | edit source]
- Edaravone (Radicava) used to treat people with Amyotrophic Lateral Sclerosis (ALS).
What are the uses of this medicine?[edit | edit source]
- This medicine is used for the treatment of amyotrophic lateral sclerosis (ALS).
How does this medicine work?[edit | edit source]
- The mechanism by which Radicava exerts its therapeutic effect in patients with ALS is unknown.
Who Should Not Use this medicine ?[edit | edit source]
This medicine cannot be used in patients:
- a history of hypersensitivity to edaravone or any of the inactive ingredients of this product.
What drug interactions can this medicine cause?[edit | edit source]
- No clinically important drug interactions have been observed with Radicava.
Is this medicine FDA approved?[edit | edit source]
- It was approved for use in the United States in 2017.
How should this medicine be used?[edit | edit source]
Recommended Dosageː The recommended dosage is 60 mg administered as an intravenous infusion over 60 minutes as follows:
- Initial treatment cycle: daily dosing for 14 days followed by a 14-day drug-free period
- Subsequent treatment cycles: daily dosing for 10 days out of 14-day periods, followed by 14-day drug-free periods
Administration
- You will be prescribed Radicava by a healthcare provider.
- Radicava will be given by intravenous (IV) infusion into your vein.
- It takes about 1 hour to receive the full dose of Radicava.
- Your healthcare provider will tell you how often you will receive Radicava.
- Your healthcare provider will monitor you closely during your treatment with Radicava.
What are the dosage forms and brand names of this medicine?[edit | edit source]
This medicine is available in fallowing doasage form:
- As Injection: 30 mg/100 mL in a single-dose polypropylene bag
This medicine is available in fallowing brand namesː
- Radicava
What side effects can this medication cause?[edit | edit source]
The most common side effects of this medicine include:
Radicava may cause serious side effects including:
- Hypersensitivity (allergic) reactions
- Sulfite allergic reactions
What special precautions should I follow?[edit | edit source]
- Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have been reported with Radicava. Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue Radicava, treat per standard of care, and monitor until the condition resolves.
- Radicava contains sodium bisulfite, a sulfite that may cause allergic type reactions, including anaphylactic symptoms and life-threatening.
What to do in case of emergency/overdose?[edit | edit source]
- In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.
- Overdose related information is also available online at poisonhelp.org/help.
- In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.
Can this medicine be used in pregnancy?[edit | edit source]
- There are no adequate data on the developmental risk associated with the use of Radicava in pregnant women.
Can this medicine be used in children?[edit | edit source]
- Safety and effectiveness of Radicava in pediatric patients have not been established.
What are the active and inactive ingredients in this medicine?[edit | edit source]
- Active ingredient: edaravone
- Inactive ingredients: L-cysteine hydrochloride hydrate, sodium bisulfite, sodium chloride, phosphoric acid, and sodium hydroxide.
Who manufactures and distributes this medicine?[edit | edit source]
- Marketed and distributed by: Mitsubishi Tanabe Pharma America, Inc., a US subsidiary of Mitsubishi Tanabe Pharma Corporation, 525 Washington Blvd., Suite 400, Jersey City, NJ 07310
What should I know about storage and disposal of this medication?[edit | edit source]
- Store at up to 25°C (77°F).
- Excursions permitted from 15°C to 30°C (59°F to 86°F) .
- Protect from light.
- Store in overwrapped package to protect from oxygen degradation until time of use.
- The oxygen indicator will turn blue or purple if the oxygen has exceeded acceptable levels.
- Once the overwrap package is opened, use within 24 hours.
Edaravone Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Deepika vegiraju